Physician profile
Anush Patel
NPI 1790986081
$562,553.96
in general payments reported to CMS, 2019-2025
40 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $29K · 2021: $71K · 2022: $84K · 2023: $134K · 2024: $96K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $266K · Travel and Lodging: $60K · Consulting Fee: $16K · Food and Beverage: $8,439 · Education: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $266,353.99 |
| Travel and Lodging | $60,148.86 |
| Consulting Fee | $15,510.00 |
| Food and Beverage | $8,439.08 |
| Education | $247.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $255,023.51 | 2019-2025 | Tagrisso, Imfinzi, Datroway |
| E.R. Squibb & Sons, L.L.C. | $124,199.47 | 2019-2025 | Opdivo, Augtyro, Opdualag |
| Regeneron Healthcare Solutions, INC. | $107,018.34 | 2021-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34,713.70 | 2019-2025 | |
| Genzyme Corporation | $12,874.23 | 2021-2024 | |
| Mirati Therapeutics, INC. | $10,454.48 | 2023 | Krazati |
| Daiichi Sankyo INC. | $6,941.06 | 2022-2025 | Datroway, Enhertu, Injectafer |
| Eisai INC. | $3,595.13 | 2020-2024 | |
| Exelixis INC. | $1,980.00 | 2021 | |
| Janssen Biotech, INC. | $1,723.10 | 2019-2025 | Rybrevant, Carvykti, Talvey |
| Karyopharm Therapeutics INC. | $1,616.20 | 2021-2024 | Xpovio |
| Novartis Pharmaceuticals Corporation | $474.21 | 2021-2025 | |
| Celgene Corporation | $472.45 | 2021-2024 | Reblozyl, Opdualag |
| Astellas Pharma US INC | $356.08 | 2023-2024 | Padcev, Xospata, Xtandi |
| Ipsen Biopharmaceuticals, INC | $190.44 | 2019-2024 | Tazverik, Onivyde |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anush Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.